Thesis icon

Thesis

Aspirin affects early phases of metastasis through the inhibition of COX-1-thromboxane A2 axis

Abstract:

Metastasis is the major cause of cancer related mortality, due to a poor understanding of the metastatic process and a subsequent lack of effective anti-metastatic therapies. Evidence from experimental studies and clinical trials has shown that aspirin reduces the incidence of distant metastases. It is well established that aspirin inhibits cyclooxygenase (COX)-1 and COX-2, triggering anti-thrombotic and anti-inflammatory effects, respectively. However, the mechanisms underlying the anti-metastatic effect of aspirin are still largely unknown.

By using an experimental model of pulmonary metastasis, we have found that the anti-metastatic effect of aspirin is associated with the inhibition of COX-1. In support of this, metastasis establishment was impaired in COX-1 deficient mice, suggesting a pivotal role of this isoform in the metastatic process. Looking in more detail into the metastatic cascade, we found that COX-1 contributes to the intravascular phase of metastasis and promotes the early persistence of tumour cells in the lung vasculature. In particular, COX-1 inhibition decreased the interaction of platelets with tumour cells and was associated with the reduction of endothelial activation, of tumour cell adhesion to the endothelium, of recruitment of metastasis-promoting monocytes/macrophages and of transendothelial migration. We have identified platelet-derived thromboxane A2 (TXA2) as the main product of COX-1 responsible for its permissive effect on metastasis. Indeed, TXA2 delivered to mice in combination with aspirin was able to abrogate the anti-metastatic effect of aspirin.

Taken together, our data suggest that the inhibition of COX-1:TXA2 axis by aspirin is sufficient to exert an anti-metastatic effect. In particular, the inhibition of platelet-derived TXA2 seems to affect multiple early steps of the haematogenous transit of tumour cells. In this perspective, TXA2 might represent a more selective therapeutic target for the prevention of metastasis.

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author

Contributors

Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Supervisor


More from this funder
Funding agency for:
Lucotti, S


Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford


Language:
English
Keywords:
UUID:
uuid:5a12480c-6b8a-4f46-b38a-4b59122e9280
Deposit date:
2017-10-26

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP